UNSPSC 51142026: Flucarbril

This classification denotes an analgesic agent with the molecular formula C11H8F3NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5XJK6U3H0P, chemically known as carbostyril, n-methyl-6-(trifluoromethyl)- but generally known as flucarbril, which bears US NIH Compound Identifier 16751. European Medicines Agency schedules Flucarbril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07668MIG. The term FLUCARBRIL is an International Non-Proprietary Name.

UNSPSC 51142026 Flucarbril, a Commodity code, designates a specific pharmaceutical active ingredient, yet recent state and local solicitations tagged with this code show minimal direct alignment with the product name itself. Instead, the opportunities reflect procurement of naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription program management — a span that suggests either misclassification in source systems or the code's application to a broader pharmaceutical procurement family. State and local buyers posting under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances administering multi-jurisdictional pharmaceutical contracts (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across Minnesota and Oregon). The work involves bulk procurement of pharmaceutical products, establishment of tiered wholesale distribution arrangements, and exploratory contracting for direct-manufacturer relationships to optimize cost and supply-chain efficiency for government health programs.

Recent activity concentrates in Florida, Texas, and the Upper Midwest cooperative-purchasing region. Seminole County, Florida posted an IFB (IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building, with electronic bidding, E-Verify compliance, and two-year initial terms plus one-year renewal options. The Texas Health and Human Services Commission issued a Request for Information (RFI No. HHS0017013, response due April 3, 2026) to gather vendor capabilities for implementing direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP (S1070000015802, due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products through three authorized wholesalers—AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC—with pricing weighted 75 percent in evaluation, cGMP and Drug Supply Chain Security Act compliance required, and contract effectiveness July 1, 2026.